Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BCYC

Bicycle Therapeutics plc

Healthcare | Biotechnology

No licensed closing price on file for BCYC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.73

Bicycle Therapeutics plc (NASDAQ: BCYC) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 12:04 UTC.

What Bicycle Therapeutics plc does

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, which are fully synthetic short peptides constrained to form two loops that enable high-affinity and selective target binding. The company uses a proprietary phage display screening platform to efficiently identify Bicycle molecules from a vast pool of potential candidates.

Summarized from Bicycle Therapeutics plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.73

Revenue, margins & earnings

FY2021: net loss $67M on revenue $12M$12MFY2021FY2022: net loss $113M on revenue $14M$14MFY2022FY2023: net loss $181M on revenue $27M$27MFY2023FY2024: net loss $169M on revenue $35M$35MFY2024FY2025: net loss $219M on revenue $73M$73MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-07
  • 2026-10-07Chief Operating OfficerSale-326$1.2K
  • 2026-10-07Chief Operating OfficerSale-30$107
  • 2026-10-06Chief Operating OfficerSale-326$1.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Bicycle Therapeutics plc do?

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, which are fully synthetic short peptides constrained to form two loops that enable high-affinity and selective target binding.

When did BCYC last file with the SEC?

Bicycle Therapeutics plc's most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:04 UTC. This page is also available as JSON at /api/data?ticker=BCYC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BCYC and 5,000+ tickers.

Create a free account — keep BCYC
For your agent
GET /api/data?ticker=BCYC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt